Search

Your search keyword '"Delforge, Michel"' showing total 116 results

Search Constraints

Start Over You searched for: Author "Delforge, Michel" Remove constraint Author: "Delforge, Michel" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
116 results on '"Delforge, Michel"'

Search Results

1. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

4. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)

5. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

8. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma

9. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

10. MM-567 Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

11. MM-491 Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

12. MM-505 Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D

13. MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

14. Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk

15. Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of the Phase 3 CASSIOPEIA Study

16. Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D

17. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

18. Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

19. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

20. Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

21. MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

23. The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

24. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

25. Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

26. P-325 Standard of care (SOC) outcomes in the last 3 years in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM): the first pooled analysis of LocoMMotion and MoMMent trials

27. P-324 LocoMMotion: a prospective, observational, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma–final analysis at 2-year follow-up

29. P-294 Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma

31. P-244 Teclistamab versus Belgian real-world clinical practice in triple-class exposed relapsed and refractory multiple myeloma patients using adjusted comparison

33. P-040 Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis

34. P-008 Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy

35. MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-up

37. CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)

38. MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups

39. MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

40. POSTER: CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)

41. POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM)

43. POSTER: MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-Up

44. POSTER: MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups

47. P-264: Updated results from LocoMMotion: A prospective, noninterventional, multinational study of real-life current standards-of-care in heavily pretreated patients with relapsed/refractory multiple myeloma

48. P-263: Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs approved therapies for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)

49. P-239: Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life standard of care (SOC) treatments: results from the LocoMMotion study

50. OAB-045: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel (cilta-cel) in lenalidomide-refractory multiple myeloma after 1–3 prior lines of therapy: CARTITUDE-2 Cohort A

Catalog

Books, media, physical & digital resources